the product in the database has an inactive status
indications:
Active immunization against invasive forms of meningococcal seropenia A and C in adults and children over 2 years. The vaccine should be used in accordance with official recommendations.
Composition:
1 dose (0.5 ml) of the reconstituted vaccine contains polysaccharidesNeisseria meningitidis from group A - 50 μg and from group C - 50 μg.
Action:
A meningococcal vaccine, obtained from purified meningococcal polysaccharidesNeisseria meningitidis groups A and C. Protective antibody levels appear 7 days after vaccination.
Contraindications:
Hypersensitivity to any of the components of the vaccine. Serious side effects after previous administration of the vaccine. Vaccination should be postponed in case of high fever or acute illness.
Precautions:
Due to the risk of immediate anaphylactic reaction, adequate medical assistance must be available during vaccination. In case of an epidemic caused by group A meningococcal disease or the risk of its occurrence if group A meningococcal protection is necessary, the vaccine can be administered to children after 6 months of age. In the case of group C, in children below 2 years of age, it is recommended to administer a group C conjugate vaccine. Vaccines must not be administered intravascularly, do not be administered intradermally.
Pregnancy and lactation:
There are no data on the use of the vaccine during pregnancy and breast-feeding. However, taking into account the severity of infection caused by meningococcal group C, pregnancy can not exclude vaccination when the risk of exposure is clearly defined. Before deciding to vaccinate a breastfeeding woman, the risk-benefit ratio should be considered.
Side effects:
Very common: headache, reactions at the injection site (transient pain, sometimes with swelling and redness), fatigue, irritability. Common: diarrhea, fever (≥38st.C). Very rarely, after placing on the market: allergenic reactions (rash, urticaria, erythema), anaphylactic reactions, lack of appetite, vomiting, irritation of the meninges, seizures, paresthesia, muscle or joint pain.
Dosage:
Subcutaneously or intramuscularly (in children up to 12 months in the anterior part of the thigh, in older patients in the shoulder muscle). Adults and children> 2 years: 1 dose (0.5 ml) of the reconstituted vaccine. Repeated vaccination is recommended within 2-4 years, depending on the age of the patient at the time of the first dose, the risk of exposure and the occurring serogroup. The vaccine should under no circumstances be mixed with other vaccines or other preparations.
(C)
